Schwere Hyponatriämie nach Kombination von Oxytocin mit Desmopressin bei postpartaler Hämorrhagie. (German)

Autor: Brandt, C. M., Benner, A., Pietsch, L., Medl, M., Kunze, M., Kalbhenn, J.

Publikováno v: Anaesthesiologie & Intensivmedizin; jun2023, Vol. 64 Issue 6, p218-223, 6p

Demonstrating Ligandability of the LC3A and LC3B Adapter Interface

Autor: Hartmann, M., Huber, J., Kramer, J.S., Heering, J., Pietsch, L., Stark, H., Odadzic, D., Bischoff, I., Fürst, R., Schröder, M., Akutsu, M., Chaikuad, A., Dötsch, V., Knapp, S., Biondi, R.M., Rogov, V.V., Proschak, E.

Autophagy is the common name for a number of lysosome-based degradation pathways of cytosolic cargos. The key components of autophagy are members of Atg8 family proteins involved in almost all steps of the process, from autophagosome formation to the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______610::7178ff64bd60c2ef274d0cf7aa555260
https://publica.fraunhofer.de/handle/publica/268858

The Dynamic Covalent Chemistry of Amidoboronates: Tuning the rac 5 /rac 6 Ratio via the B-N and B-O Dynamic Covalent Bonds.

Autor: Harders P; Otto Diels Institute of Organic Chemistry, Christian-Albrechts-Universität zu Kiel, Otto-Hahn-Platz 4, 24098, Kiel, Germany., Griebenow T; Otto Diels Institute of Organic Chemistry, Christian-Albrechts-Universität zu Kiel, Otto-Hahn-Platz 4, 24098, Kiel, Germany., Businski A; Otto Diels Institute of Organic Chemistry, Christian-Albrechts-Universität zu Kiel, Otto-Hahn-Platz 4, 24098, Kiel, Germany., Kaus AJ; Otto Diels Institute of Organic Chemistry, Christian-Albrechts-Universität zu Kiel, Otto-Hahn-Platz 4, 24098, Kiel, Germany., Pietsch L; Otto Diels Institute of Organic Chemistry, Christian-Albrechts-Universität zu Kiel, Otto-Hahn-Platz 4, 24098, Kiel, Germany., Näther C; Institute of Inorganic Chemistry, Christian-Albrechts-Universität zu Kiel, Max-Eyth-Straße 2, 24118, Kiel, Germany., McConnell AJ; Otto Diels Institute of Organic Chemistry, Christian-Albrechts-Universität zu Kiel, Otto-Hahn-Platz 4, 24098, Kiel, Germany.

Publikováno v: ChemPlusChem [Chempluschem] 2022 May; Vol. 87 (5), pp. e202200085. Date of Electronic Publication: 2022 Mar 22.

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1 ^T315I and BCR-ABL1 ^T315I-E255K .

Autor: Mian AA; Department of Hematology, Division of Cancer and Genetics, and Experimental Clinical Medical Center (ECMC), Medical School, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.; Center for Regenerative Medicine and Stem Cell Research, Aga Khan University, Karachi, Pakistan., Haberbosch I; Department of Internal Medicine II, Goethe University, Frankfurt, Germany., Khamaisie H; Department of Nutrition and Natural Products, Migal-Galilee Technology Center, PO Box 831, 11016, Kiryat Shmona, Israel., Agbarya A; Oncology Department, Bnai Zion MC, Haifa, Israel., Pietsch L; Department of Internal Medicine I, Clinic of Goethe University, Frankfurt, Germany.; German Cancer Consortium (DKTK), Frankfurt, Germany., Eshel E; Hematology Institute, Ziv Medical Center, Azrieli Faculty of Medicine, Bar Ilan University, Zfat, Israel., Najib D; Hematology Institute, Ziv Medical Center, Azrieli Faculty of Medicine, Bar Ilan University, Zfat, Israel., Chiriches C; Department of Hematology, Division of Cancer and Genetics, and Experimental Clinical Medical Center (ECMC), Medical School, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK., Ottmann OG; Department of Hematology, Division of Cancer and Genetics, and Experimental Clinical Medical Center (ECMC), Medical School, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK., Hantschel O; Swiss Institute for Experimental Cancer Research, School of Life Sciences, École polytechnique fédérale de Lausanne, Lausanne, Switzerland.; Medical Biochemistry and Pharmacology Center, Institute for Physiological Chemistry, Philipps-University, Marburg, Germany., Biondi RM; Department of Internal Medicine I, Clinic of Goethe University, Frankfurt, Germany.; German Cancer Consortium (DKTK), Frankfurt, Germany.; Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA)-CONICET-Partner Institute of the Max Planck Society, Buenos Aires, Argentina., Ruthardt M; Department of Hematology, Division of Cancer and Genetics, and Experimental Clinical Medical Center (ECMC), Medical School, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK. ruthardtm@cardiff.ac.uk., Mahajna J; Department of Nutrition and Natural Products, Migal-Galilee Technology Center, PO Box 831, 11016, Kiryat Shmona, Israel. jamalm@migal.org.il.; The Department of Nutritional Sciences, Tel Hai Academic College, Kiryat Shmona, Israel. jamalm@migal.org.il.

Publikováno v: Annals of hematology [Ann Hematol] 2021 Aug; Vol. 100 (8), pp. 2023-2029. Date of Electronic Publication: 2021 Jun 10.

Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.

Autor: Hartmann M; Institute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany., Huber J; Institute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance Goethe-University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany., Kramer JS; Institute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany., Heering J; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany., Pietsch L; Department of Internal Medicine I, Goethe University Hospital Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany., Stark H; German translational cancer network (DKTK), site Frankfurt/Mainz, 60438 Frankfurt, Germany.; Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, 40225 Duesseldorf, Germany., Odadzic D; German translational cancer network (DKTK), site Frankfurt/Mainz, 60438 Frankfurt, Germany., Bischoff I; Institute of Pharmaceutical Biology, Goethe-University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany., Fürst R; Institute of Pharmaceutical Biology, Goethe-University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany., Schröder M; Institute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany., Akutsu M; Buchmann Institute for Molecular Life Sciences, Goethe-University Frankfurt, Max-von-Laue-Str. 15, 60438 Frankfurt, Germany., Chaikuad A; Institute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany., Dötsch V; Institute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance Goethe-University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany., Knapp S; Institute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany.; German translational cancer network (DKTK), site Frankfurt/Mainz, 60438 Frankfurt, Germany., Biondi RM; Department of Internal Medicine I, Goethe University Hospital Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany., Rogov VV; Institute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany.; Institute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance Goethe-University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany., Proschak E; Institute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany.; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany.; German translational cancer network (DKTK), site Frankfurt/Mainz, 60438 Frankfurt, Germany.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2021 Apr 08; Vol. 64 (7), pp. 3720-3746. Date of Electronic Publication: 2021 Mar 26.